What is Roth Capital’s Estimate for BRTX Q3 Earnings?

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Equities research analysts at Roth Capital upped their Q3 2024 earnings estimates for shares of BioRestorative Therapies in a report issued on Tuesday, November 5th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.36). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.83) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.76) EPS, FY2025 earnings at ($1.12) EPS and FY2026 earnings at ($1.18) EPS.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.06. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the company posted ($0.77) earnings per share.

Separately, Roth Mkm lifted their target price on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Stock Up 6.5 %

NASDAQ BRTX opened at $1.65 on Thursday. The company’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.58. The stock has a market cap of $11.42 million, a P/E ratio of -0.81 and a beta of 63.40. BioRestorative Therapies has a twelve month low of $1.03 and a twelve month high of $3.67.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.